Bioxytran, Inc. (BIXT)
OTCMKTS · Delayed Price · Currency is USD
0.0233
-0.0009 (-3.72%)
Jul 22, 2026, 11:59 AM EST
Bioxytran Employees
Bioxytran had 2 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
2
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,419,216
Market Cap
2.73M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 2 | 0 | - |
| Dec 31, 2024 | 2 | -1 | -33.33% |
| Dec 31, 2023 | 3 | 1 | 50.00% |
| Dec 31, 2022 | 2 | 0 | - |
| Dec 31, 2021 | 2 | 0 | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| CASI Pharmaceuticals | 214 |
| Vaccinex | 27 |
| America Great Health | 5 |
| AccuStem Sciences | 4 |
| Bio-Path Holdings | 1 |
Bioxytran News
- 7 weeks ago - Bioxytran Highlights New Book on Real-Time Monitoring Tissue Oxygenation Relevant to Oxygen Carrier BXT-25 - GlobeNewsWire
- 2 months ago - Bioxytran Quarterly report: Q1 2026 - Filings
- 3 months ago - Bioxytran Annual report: Q4 2025 - Filings
- 4 months ago - BIOXYTRAN, INC. COMPLETES $1.2 MILLION PRIVATE PLACEMENT - GlobeNewsWire
- 5 months ago - Bioxytran Announces Positive Dose Optimization Results and Advances Toward Phase 3 Registrational Trial for ProLectin-M - GlobeNewsWire
- 5 months ago - Bioxytran, Inc. Reports Positive Phase 1b/2a Clinical Study Results for ProLectin-M, a Broad-Range Antiviral Drug in Mild to Moderate COVID-19 - Accesswire
- 5 months ago - Bioxytran Reports Positive Phase 2 Results Demonstrating Rapid Viral Clearance with ProLectin-MBioxytran - GlobeNewsWire
- 6 months ago - Bioxytran Transcript: Noble Capital Markets’ Emerging Growth Virtual Equity Conference - Transcripts